The association that GD has with atopic dermatitis has raised suspicion of a potential immune-mediated pathogenesis, and has consequently encouraged some clinicians to treat refractory GD with immune-modulators like dupilumab, an interleukin (IL)-4 and IL-13 inhibitor [4,5]. This evidence concerns the gene IL13 and atopic eczema.